GBM and KIRC are a few examples; also, PD-1 inhibitors (Nivolumab, Pembrolizumab, and Cemiplimab), PDL-1 inhibitors (Atezolizumab, Durvalumab, and Avelumab), CTLA-4 inhibitors (Ipilimumab) are approved by the USFDA for the treatment of cancers. This evidence concerns the gene CD274 and cancer.